🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › Utah

Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Utah

14 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Utah.

Mga Lungsod sa Utah

Opisyal na teksto ng pag-aaral (English)

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Intermountain Medical Center ( Site 0182), Murray
  • Intermountain Healthcare - St. George ( Site 0203), St. George
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06890884

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  • Community Cancer Trials of Utah, Ogden
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06091865

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Intermountain Healthcare, Salt Lake City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
Nagre-recruitPhase 1/2
6 Months – 25 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06395103

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
  • Intermountain Health LDS Hospital, Salt Lake City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT06500273

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

  • Huntsman Cancer Institute, Salt Lake City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06227026

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Huntsman Cancer Institute, Salt Lake City
  • Intermountain Healthcare, Salt Lake City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Intermountain Healthcare, Salt Lake City
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 10, 2026 · NCT05077527

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

  • Huntsman Cancer Institute at University of Utah, Salt Lake City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT07528352

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

  • Huntsman Cancer Institute, University of Utah, Salt Lake City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT04775745

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 20, 2025 · NCT05890352

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 26, 2024 · NCT06238648

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.